If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEden Research Regulatory News (EDEN)

Share Price Information for Eden Research (EDEN)

Share Price is delayed by 15 minutes
Get Live Data
2.90    0.05 (1.75%)
Bid:
2.80
Ask:
3.00
Spread: 0.20 (7.143%)
Market Cap: £23.30m
EDEN Live PriceLast checked at - London Stock Exchange

Intraday Eden Research Share Chart

Active substances approved for MRL exemption

25 Jun 2015 07:00

RNS Number : 1595R
Eden Research plc
25 June 2015
 



 

Eden Research plc

("Eden" or "Company")

 

Active substances approved for maximum residue level exemption

 

Eden Research Plc (AIM: EDEN), the AIM-listed natural micro-encapsulation company, announces that it has received notice that the three active ingredients, which form part of multiple plant protection products developed by Eden, have been granted approval for inclusion in Annex IV to Regulation (EC) Number 396/2005, subject to the provision of confirmatory data.

 

Geraniol and thymol are now exempt from the maximum residue levels ("MRLs") set for many pesticides. This translates into a clear benefit for growers when considering treatment programmes, as Eden's products can now be used without regard to concern for residues, thus allowing growers to protect their crops right up to the point of harvest. Eugenol has previously been granted provisional approval for inclusion in Annex IV.

 

Eden's Chief Executive, Sean Smith, stated: "Eden and its licensees have long been aware of the potential for our naturally-derived pesticide products to deliver additional benefits to growers through their use late in the season, thereby protecting crops at a critical time and allowing maximum produce quality. Now the European Commission has helped growers to fully realise these additional benefits by granting products containing our core actives an exemption from maximum residue levels. Grape growers, for example, will no longer need to balance their desire to select an optimal harvest time to increase produce quality and sugar levels with the requirement to adhere to maximum residue levels for their late-season fungicidal treatment. This translates into a benefit for growers and our commercialisation partners, and it strengthens the overall value of Eden's product offerings."

 

Eden's first product, 3AEY, was recently granted authorisation by the zonal Rapporteur Member State, Malta for the prevention and cure of botrytis in table and wine grapes. Following this authorisation, the concerned Member States in the Southern regulatory zone have 120 days to issue their national authorisations, thereby allowing sales in key grape growing countries, including three of the top five global grape producers. Eden's commercialisation partners such as Sipcam, Redestos and Sumi Agro France are now preparing for product launches following authorisation.

 

Enquiries:

 

Eden Research plc

www.edenresearch.com

Sean Smith, Chief Executive Officer

Tel: 01285 359 555

Alex Abrey, Chief Financial Officer

W H Ireland Limited

www.wh-ireland.co.uk

John Wakefield / Ed Allsopp

Tel: 0117 945 3471

Walbrook PR Ltd

Tel: 020 7933 8780 or eden@walbrookpr.com

Paul McManus

Mob: 07980 541 893

Lianne Cawthorne

Mob: 07584 391 303

 

 

 

 

Notes:

 

Eden is an early stage revenue company with intellectual property and expertise in encapsulation, terpenes and environmentally friendly technologies to provide naturally occurring solutions to the global agrochemicals industry, the animal health industry, and consumer products.

 

Eden's encapsulation technology harnesses the biocidal efficacy of naturally occurring chemicals produced by plants (terpenes) and can also be used with hydrophobic compounds both natural and synthetic. The technology uses yeast cells to deliver a slow release of natural compounds for agricultural and non-agricultural uses. Terpenes are already widely used in the food flavouring, cosmetic and pharmaceutical industries.

 

Historically, terpenes have had limited commercial use in the agrochemical sector due to their volatility, phytotoxicity and poor solubility. Eden's platform encapsulation technology provides a unique, environmentally friendly solution to these problems and enables terpenes to be used as effective, low-risk agrochemicals.

 

With leading consultants in their respective fields, the Company is developing these technologies through innovative research and a series of commercial production, marketing and distribution partnerships.

 

The Company has a number of patents and has a pipeline of products at differing stages of development targeting specific areas of the global agrochemicals industry. To date, the Company has invested in the region of £12m in developing and protecting its intellectual property. Revenues earned by the Company have been modest whilst the Company has concentrated on securing patent protection for its intellectual property, identifying suitable industrial partners and entering into licence agreements.

 

Eden was admitted to trading on AIM on 11 May 2012 and trades under the symbol EDEN.

 

For more information about Eden, please visit www.edenresearch.com

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCUSOARVNANUUR
Date   Source Headline
5th Jan 20217:00 amRNSGreen Economy Mark
2nd Nov 20207:00 amRNSEden partners with M H Poskitt
13th Oct 20207:00 amRNSChange of Registered Office
29th Sep 20207:00 amRNSHalf-year Report
17th Sep 20207:00 amRNSNew authorisations for Cedroz™ and Mevalone®
15th Sep 20207:00 amRNSKey patent granted for Eden’s Sustaine technology
1st Sep 20207:00 amRNSRegulatory approval for Cedroz™ in Spain
25th Aug 20207:00 amRNSNew authorisation for bio-fungicide in Australia
5th Aug 20207:00 amRNSNew authorisation for Cedroz™ in Greece
10th Jul 20207:00 amRNSAppointment of Global Head of Biology and Dev
1st Jul 20207:00 amRNSNew office and laboratory in Oxfordshire
25th Jun 20207:00 amRNSPatents granted in the United States
24th Jun 202012:20 pmRNSResult of AGM
29th May 20207:58 amRNSIssuing of Annual Report & Notice of AGM
27th May 20207:00 amRNSUpdate on Bayer Animal Health Agreement
20th May 20207:00 amRNSNew authorisations for Cedroz and Mevalone
7th May 20207:00 amRNSFinancial Results for Year Ended 31 December 2019
6th May 20205:09 pmRNSNotice of Results
15th Apr 20207:00 amRNSAppointment of Director of Regulatory Affairs
8th Apr 202010:03 amRNSOrganic farming certification in Italy and Spain
24th Mar 20208:20 amRNSHolding(s) in Company
20th Mar 20205:33 pmRNSHolding(s) in Company
20th Mar 20203:37 pmRNSHolding(s) in Company
20th Mar 202010:33 amRNSHolding(s) in Company
18th Mar 202011:18 amRNSResults of General Meeting & Open Offer
5th Mar 20207:00 amRNSDirector/PDMR Shareholding
28th Feb 20201:35 pmRNSPlacing, Subscription & Open Offer
20th Jan 20207:00 amRNSAppointment of Hawthorn Advisors
14th Jan 20207:00 amRNSYear-end trading update
8th Jan 20207:00 amRNSAgreement with Corteva Agriscience
7th Jan 20207:00 amRNSRegulatory Approval- Organic Production Regulation
23rd Dec 20197:00 amRNSAgreement with Sipcam Oxon in Portugal and Benelux
19th Dec 20197:00 amRNSApproval of Cedroz in Mexico
17th Dec 20197:00 amRNSDistribution Agreement with SumiAgro Europe
16th Oct 201912:48 pmRNSDirector/PDMR Shareholding
16th Oct 20197:00 amRNSCedroz Approval
18th Sep 20197:00 amRNSHalf Yearly Report
29th Jul 20197:00 amRNSGrant of 'Emergency use' authorisation
8th Jul 20197:00 amRNSChange of Adviser
28th Jun 20192:42 pmRNSReplacement - Grant of Awards
28th Jun 201911:43 amRNSGrant of Awards under Long-Term Incentive Plan
28th Jun 20197:00 amRNSDirector/PDMR Shareholding
12th Jun 20197:00 amRNSAppointment of Commercial Director
15th May 20198:10 amRNSResult of AGM
14th May 20197:00 amRNSAGM Statement
9th May 20197:00 amRNSSales of Cedroz commence in Italy
26th Apr 20197:00 amRNSItaly grants "emergency use" Cedroz authorisation
16th Apr 201912:43 pmRNSDirector/PDMR Shareholding
16th Apr 20197:00 amRNSIssuing of Annual Report & Notice of AGM
2nd Apr 20197:00 amRNSFinancial Results for Year Ended 31 December 2018

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.